Resource Room

Infigratinib scientific resources

05.29.2020

Infigratinib in advanced/unresectable or metastatic urothelial carcinoma demonstrates consistent treatment response in both first-line and later-line treatment settings
Yung Lyou et al.

05.29.2020

PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations
Siamak Daneshmand, Petros Grivas, Srikala S. Sridhar, Shilpa Gupta, Joaquim Bellmunt, Guru Sonpavde, Mark T. Fleming, Seth P. Lerner, Yohann Loriot, Hao Wang, Hiywot Takkele, Corina Andresen, Jessica Rearden, Stacie Shepherd, Sumanta K. Pal

05.29.2020

A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions
Milind M. Javle, Saeed Sadeghi, Anthony B. El-Khoueiry, Lipika Goyal, Philip Agop Philip, Robin Kate Kelley, Ivan Borbath, Teresa Macarulla, Wei-Peng Yong, Suebpong Tanasanvimon, Amit Pande, Ai Li, Michael Howland, Stacie Shepherd, Ghassan K. Abou-Alfa

05.08.2020

Low-dose infigratinib treatment does not lead to changes in phosphorus in preclinical animal studies
Maribel Reyes, PhD, Uma Sinha, PhD, Gary Li, PhD, David Martin, PhD

05.08.2020

Prospective clinical assessment study in children with achondroplasia: the PROPEL trial
Ravi Savarirayan, Peter Kannu, Carl L. Dambkowski, Daniela Rogoff, Melita Irving

05.08.2020

FGFR-selective tyrosine kinase inhibitors, such as infigratinib, show potency and selectivity for FGFR3 at pharmacologically relevant doses for the potential treatment of achondroplasia
Katherine Dobscha, MBA, Ge Wei, PhD, Carl L Dambkowski, MD, Daniela Rogoff, MD, PhD

05.08.2020

Support for a new therapeutic approach of using a low-dose FGFR tyrosine kinase inhibitor (infigratinib) for achondroplasia
Benoit Demuynck, Justine Filpo, Gary Li, Carl Dambkowski, Laurence Legeai-Mallet

06.03.2019

Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial
Javle M et al. Presented at the American Society of Clinical Oncology 2019 Annual Meeting; May 31-June 4, 2019; Chicago, IL.

06.03.2019

Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results
Dizman N et al. Presented at the American Society of Clinical Oncology 2019 Annual Meeting; May 31-June 4, 2019; Chicago, IL.

10.19.2018

A phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor (TKI), in patients with previously-treated advanced cholangiocarcinoma containing FGFR2 fusions
Javle M et al. Presented at the European Society for Medical Oncology 2018 Congress; October 19-23, 2018; Munich, Germany.

05.30.2018

Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations
Pal SK et al. Published in Cancer Discovery.

04.11.2016

Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model
Komla-Ebri D et al. Published in The Journal of Clinical Investigation.